Trademark: 90796010
Word
EPICENTRX
Status
Pending
Status Code
731
Status Date
Wednesday, January 3, 2024
Serial Number
90796010
Mark Type
4000
Filing Date
Friday, June 25, 2021
Published for Opposition
Tuesday, November 8, 2022

Trademark Owner History
EpicentRx, Inc. - Owner At Publication

Classifications
5 Pharmaceutical products, preparations, and substances for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; biological products, preparations, and substances being medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; immunotherapies in the nature of medical preparations for the prevention and treatment of cancer, infectious diseases, allergies, mental illnesses, chemotherapy side effects, radiation side effects, transplantation side effects, and viral, metabolic, cardiovascular, vascular, pulmonary, blood, dermatologic, fibrotic, autoimmune, inflammatory, neurodegenerative, neuromuscular, dietary deficiency, hereditary, endocrine, eye, ear, and voice related diseases and disorders; vaccines; pharmaceuticals in the nature of biotechnology platform technology, namely, viral and vaccine vectors for delivery and insertion of function-altering genetic material into human and animal patients, plants, and crops, for visualization of specific cell types, for inducing humoral and cell-mediated responses, for targeting and killing cancer cells, for removing pathological functions, for controlling biological pests, and for boosting crop yields; chemical platform technology, namely, small molecule compounds being pharmaceuticals for inducing the expression of antioxidant, anti-inflammatory, and cytoprotective proteins in non-malignant tissues, for activating the immune system, for modulating blood flow in ischemic tissues, for upregulating proinflammatory mediators in tumors, and for treating plant diseases
42 Scientific and medical research and development in the fields of pharmaceuticals, biologics, agriculture, pest control, biotechnology, immunotherapies, and vaccines
EPICENT RX

Trademark Events
Jan 5, 2024
Notice Of Approval Of Extension Request E-Mailed
Jan 3, 2024
Sou Extension 2 Granted
Jan 3, 2024
Sou Extension 2 Filed
Jan 3, 2024
Sou Teas Extension Received
Dec 22, 2023
Teas Change Of Correspondence Received
Dec 22, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Dec 22, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jul 5, 2023
Notice Of Approval Of Extension Request E-Mailed
Jul 3, 2023
Sou Extension 1 Granted
Jul 3, 2023
Sou Extension 1 Filed
Jul 3, 2023
Sou Teas Extension Received
Jan 3, 2023
Noa E-Mailed - Sou Required From Applicant
Nov 8, 2022
Official Gazette Publication Confirmation E-Mailed
Nov 8, 2022
Published For Opposition
Oct 19, 2022
Notification Of Notice Of Publication E-Mailed
Oct 3, 2022
Approved For Pub - Principal Register
Sep 23, 2022
Teas/Email Correspondence Entered
Sep 22, 2022
Correspondence Received In Law Office
Sep 22, 2022
Teas Response To Office Action Received
Mar 22, 2022
Notification Of Non-Final Action E-Mailed
Mar 22, 2022
Non-Final Action E-Mailed
Mar 22, 2022
Non-Final Action Written
Mar 16, 2022
Assigned To Examiner
Sep 9, 2021
New Application Office Supplied Data Entered
Jun 29, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24